Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Medicine

Vol 9 No 2 (2024): December

Evaluation of Some Hematological Parameters in HCV Infected Patients Among Blood Donors at Thi-Qar Province
Evaluasi Beberapa Parameter Hematologi pada Pasien yang Terinfeksi HCV di Antara Donor Darah di Provinsi Thi-Qar



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.10402
Published
December 13, 2024

Abstract

Hepatitis C virus is a major health problem because of its effect on the liver and health and its being life-threatening if not treated early. It also affects the blood parameters of those infected. The current study conducted in Thi-Qar province revealed changes in some blood parameters of the infected group compared to the control group, where a slight decrease was recorded in WBCs, RBCs,  PCV, MCV, MCH, PLT, Lymp. but no significant differences were found, except for red blood cells, which were 0.03 at a significant level 0.05. It was also found that the highest infection rate was in the age group of 30-39 years, while no infection was recorded in the age group of 50-59 years.

Highlights:

  1. Hepatitis C impacts liver health and alters blood parameters.
  2. Significant RBC change noted; highest infection in 30–39 age group.
  3. No infections in the 50–59 age group recorded.
Keywords: HCV, Hematological, ELISA, Thi-Qar

References

  1. . T. Stroffolini and G. Stroffolini, “Prevalence and Modes of Transmission of Hepatitis C Virus Infection: A Historical Worldwide Review,” Viruses, vol. 16, no. 7, p. 1115, Jul. 2024, doi: 10.3390/v16071115.
  2. . M. Ren, C. Lu, M. Zhou, X. Jiang, X. Li, and N. Liu, “The intersection of virus infection and liver disease: A comprehensive review of pathogenesis, diagnosis, and treatment,” WIREs Mechanisms of Disease, vol. 16, no. 3, Jan. 2024, doi: 10.1002/wsbm.1640.
  3. . J. Paul, “Introduction to Infectious Diseases,” in Springer eBooks, 2024, pp. 1–63. doi: 10.1007/978-3-031-28567-7_1.
  4. . J. Shadymanova and N. Musaeva, “4. HIV and Hepatitis C in Kyrgyzstan,” in Nomos Verlagsgesellschaft mbH & Co. KG eBooks, 2024, pp. 109–140. doi: 10.5771/9783748920021-109.
  5. . S. Younas et al., “Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients,” The Journal of Infection in Developing Countries, vol. 15, no. 10, pp. 1489–1496, Oct. 2021, doi: 10.3855/jidc.12912.
  6. . F. Roudot-Thoraval, “Epidemiology of hepatitis C virus infection,” Clinics and Research in Hepatology and Gastroenterology, vol. 45, no. 3, p. 101596, Feb. 2021, doi: 10.1016/j.clinre.2020.101596.
  7. . M. Martinello, S. Bajis, and G. J. Dore, “Progress Toward Hepatitis C Virus Elimination,” Gastroenterology Clinics of North America, vol. 49, no. 2, pp. 253–277, Mar. 2020, doi: 10.1016/j.gtc.2020.01.005.
  8. . Q. U. Ain, H. Zameer, A. Haroon, S. Kadir, N. Mazhar, and T. Laique, “Haematological Changes in Hepatitis C (HCV) Patients,” Pakistan Journal of Medical & Health Sciences, vol. 16, no. 4, pp. 126–127, Apr. 2022, doi: 10.53350/pjmhs22164126.
  9. . S. Tanwar, F. Rhodes, A. Srivastava, P. M. Trembling, and W. M. Rosenberg, “Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C,” World Journal of Gastroenterology, vol. 26, no. 2, pp. 109–133, Jan. 2020, doi: 10.3748/wjg.v26.i2.109.
  10. . M. Yang et al., “Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States,” Scientific Reports, vol. 10, no. 1, Dec. 2020, doi: 10.1038/s41598-020-77515-y.
  11. . Y. Zou et al., “Epidemiology of acute hepatitis C and hepatitis C virus-related cirrhosis in reproductive-age women, 1990–2019: An analysis of the Global Burden of Disease study,” Journal of Global Health, vol. 14, Apr. 2024, doi: 10.7189/jogh.14.04077.
  12. . S. Chacko and S. Samanta, “‘Hepatocellular carcinoma: A life-threatening disease,’” Biomedicine & Pharmacotherapy, vol. 84, pp. 1679–1688, Nov. 2016, doi: 10.1016/j.biopha.2016.10.078.
  13. . M. S. Dar, S. Gupta, and O. Gowhar, “Estimation of hematological parameters in patients with Hepatitis B and C,” IAIM, vol. 11–11, pp. 76–80, Nov. 2019, [Online]. Available: https://www.iaimjournal.com/storage/2019/11/iaim_2019_0611_12.pdf
  14. . D. Chettan, et al. "To Study the Spectrum of Haematological Findings in HCV Positive Patients Based on CBC, PBF and Bone Marrow Findings." (2022): 758-763.
  15. . H. Rasheed et al., “Altered Hematological Parameters in HCV Infection: A Diagnostic Approach,” ajhs.biomedpress.org, Nov. 2022, doi:10.15419/ajhs.v8i2.517.
  16. . S. Rawi and G. Y. Wu, “Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review,” Journal of Clinical and Translational Hepatology, vol. 8, no. 2, pp. 184–191, Apr. 2020, doi: 10.14218/jcth.2020.00007.
  17. . M. G. Hofmeister et al., “Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016,” Hepatology, vol. 69, no. 3, pp. 1020–1031, Nov. 2018, doi: 10.1002/hep.30297.
  18. . A. Petruzziello, S. Marigliano, G. Loquercio, A. Cozzolino, and C. Cacciapuoti, “Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes,” World Journal of Gastroenterology, vol. 22, no. 34, p. 7824, Jan. 2016, doi: 10.3748/wjg.v22.i34.7824.
  19. . A. U. Rehman, F. Ali, M. Ali, I. Alam , A. W. Khan. "Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients". Asian Pac J Cancer Prev. 2016;17(5):2485-90. PMID: 27268618.
  20. . M.-H. Tsai et al., “Predictors for Early Identification of Hepatitis C Virus Infection,” BioMed Research International, vol. 2015, pp. 1–7, Jan. 2015, doi: 10.1155/2015/429290.
  21. . A. M. Constantinescu et al., “Evaluating the Hematological Parameter Alterations Induced by Mavyret in Chronic Hepatitis Patients,” Gastrointestinal Disorders, vol. 6, no. 4, pp. 832–841, Oct. 2024, doi: 10.3390/gidisord6040058.
  22. . R. S. Brown et al., “Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial,” Journal of Hepatology, vol. 72, no. 3, pp. 441–449, Nov. 2019, doi: 10.1016/j.jhep.2019.10.020.
  23. . M. Olariu, C. Olariu, and D. Olteanu, “Thrombocytopenia in chronic hepatitis C.,” 2010. https://www.semanticscholar.org/paper/Thrombocytopenia-in-chronic-hepatitis-C.-Olariu-Olariu/efcf3d4d1265c913975 8e813c06ad7f497421b77.
  24. . X. Forns et al., “Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts,” Advances in Therapy, vol. 38, no. 6, pp. 3409–3426, May 2021, doi: 10.1007/s12325-021-01753-3.
  25. . E. J. Smolders, A. M. E. Jansen, P. G. J. Ter Horst, J. Rockstroh, D. J. Back, and D. M. Burger, “Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update,” Clinical Pharmacokinetics, vol. 58, no. 10, pp. 1237–1263, May 2019, doi: 10.1007/s40262-019-00774-0.
  26. . C. C. Chen et al., “Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin,” Journal of the Formosan Medical Association, vol. 119, no. 1, pp. 532–537, Aug. 2019, doi: 10.1016/j.jfma.2019.07.028.
  27. . E. A. Alsaadi et al. "The Prevalence of Hepatitis B virus and Hepatitis C virus Infection among Blood Donors in Thi-Qar Blood Bank from 2020 to 202". Karbala Journal of Pharmaceutical Sciences, 1(21).‏ 2023
  28. . Z. Khan, “Incidence of Hepatitis C virus infection in Swat District, Pakistan: a preliminary study,” Pure and Applied Biology, vol. 11, no. 1, May 2021, doi: 10.19045/bspab.2022.110006.
  29. . H. A. M. A. Mula and M. H. A. Ammar, “Determination of IL-7 serum levels on hepatitis-C progression in HCV infected patients,” International Journal of Health Sciences, pp. 8037–8042, Jul. 2022, doi: 10.53730/ijhs.v6ns4.11356.
  30. . Khalaf and K. Hussein, “Assessment of Hepatitis C virus (HCV) associated with hemodialysis patients in Thi-Qar province, Iraq,” Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9 September 2021, Sakarya, Turkey, Jan. 2022, doi: 10.4108/eai.7-9-2021.2315370.

Downloads

Download data is not yet available.